NANO MRNA Co., Ltd. is a biotech venture specializing in mRNA therapeutics. The company is expanding its pipeline through collaborations and partnerships, with high expectations for treating intractable cancers.
NANO MRNA Co., Ltd. has been developing innovative pharmaceuticals, primarily focusing on anticancer drugs that encapsulate small molecules and other medicines within nanoparticles using micellar nanoparticle technology. In January 2023, the company shifted its business model to concentrate on mRNA therapeutics. mRNA therapeutics involve administering artificially manufactured mRNA to the body, enabling the expression of proteins encoded by the mRNA to prevent or treat diseases. The company is advancing multiple mRNA pipelines, including regenerative medicine for osteoarthritis of the knee, immune tolerance vaccines, and preventive vaccines for infectious diseases. NANO MRNA conducts research and development up to the preclinical trial stage and then licenses out to pharmaceutical companies. The company actively pursues joint research with academia, pharmaceutical, and non-pharmaceutical companies to expand its pipeline of new candidates. In addition to mRNA, NANO MRNA continues to develop brain tumor treatments and siRNA drugs targeting transcription factors. The company aims to establish a development system rivaling major pharmaceutical companies and create innovative medicines.